Genomic Health announces publication of data demonstrating that the Oncotype DX breast cancer test significantly influences breast cancer treatment decisions, while increasing physician confidence and patient satisfaction.

Genomic Health Inc announced the publication of a prospective, multi-centre, study that showed the Oncotype DX breast cancer test Recurrence Score had a significant impact on breast cancer treatment decisions for early-stage breast cancer patients while increasing patient satisfaction and physician confidence in those decisions. The study found that knowledge of a patient's Recurrence Score changed oncologists' treatment recommendations in 31.5% of cases and changed 27% of breast cancer patients' treatment decisions. The Oncotype DX breast cancer test measures the expression of 21 genes of an individual tumour to generate a Recurrence Score result that quantifies the magnitude of …